MedPath

SARS-CoV-2 vaccine

Generic Name
SARS-CoV-2 vaccine
Drug Type
Biotech
Background

SARS-CoV-2 vaccine is an adjuvanted recombinant protein-based COVID-19 vaccine candidate being developed collaboratively by GlaxoSmithKline (GSK) and Sanofi. This vaccine candidate is composed of a spike protein antigen which aims to stimulate immune system production of antibodies against SARS-CoV-2; it uses technology previously employed for a recombinant influenza vaccine.

Clinical Trials
Related News

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Phase 3
Recruiting
Conditions
COVID-19
Influenza
Interventions
Biological: Licensed Influenza Vaccine
Other: Placebo
First Posted Date
2024-11-19
Last Posted Date
2025-03-18
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
2450
Registration Number
NCT06694389
Locations
🇯🇵

Fukuoka Heartnet Hospital, Fukuoka-shi, Fukuoka, Japan

🇯🇵

Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical, Sapporo-shi, Hokkaido, Japan

🇯🇵

Motomachi Takatsuka Naika Clinic - Internal Medicine, Yokohama-shi, Kanagawa, Japan

and more 42 locations

IMPACT OF KIDNEY FAILURE ON THE REGULATION OF HUMORAL RESPONSE TO VACCINATION

Not yet recruiting
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Vaccine Response
Interventions
Biological: Influenza vaccination
First Posted Date
2024-10-10
Last Posted Date
2024-10-10
Lead Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Target Recruit Count
146
Registration Number
NCT06635525
Locations
🇮🇹

ASST Santi Paolo e Carlo, Milano, Italy

🇮🇹

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

🇮🇹

ASST Fatebenefratelli Sacco, Milano, Italy

Vaccine Responses in Cancer

Recruiting
Conditions
Viral Vaccines
Interventions
Biological: Influenza vaccination
Biological: Zoster Vaccine Recombinant
First Posted Date
2024-09-20
Last Posted Date
2024-09-20
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
250
Registration Number
NCT06605625
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed

Completed
Conditions
SARS-CoV-2 RNA Vaccines
HIV Infection
Interventions
First Posted Date
2022-12-01
Last Posted Date
2024-10-11
Lead Sponsor
Hospitales Universitarios Virgen del Rocío
Target Recruit Count
48
Registration Number
NCT05633927
Locations
🇪🇸

Virgen del Rocio University Hospital, Sevilla, Spain

COVID-19 Vaccines Associated Malaise

Completed
Conditions
Vaccine Adverse Reaction
Interventions
First Posted Date
2022-02-10
Last Posted Date
2022-05-05
Lead Sponsor
University Hospital, Caen
Target Recruit Count
1534706
Registration Number
NCT05234333
Locations
🇫🇷

Caen University Hospital, Department of Pharmacology, Caen, Normandie, France

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)

Active, not recruiting
Conditions
Kidney Transplant Infection
SARS-CoV Infection
Interventions
First Posted Date
2021-02-10
Last Posted Date
2024-04-04
Lead Sponsor
Oslo University Hospital
Target Recruit Count
150
Registration Number
NCT04747522
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy